EF
SAGE

Empirical Finance’s Sage Therapeutics SAGE Stock Holding History

Empirical Finance’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,745
Closed -$223K – 496
2022
Q1 		$223K Hold
6,745
– – 0.03% 462
2021
Q4 		$287K Sell
6,745
-5,844
-46% -$245K 0.03% 414
2021
Q3 		$558K Hold
12,589
– – 0.08% 244
2021
Q2 		$715K Buy
+12,589
New +$890K 0.12% 200

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Empirical Finance's SAGE Position: Q2 2022 in Review

Empirical Finance sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 6,745 shares — an estimated $223K sold.

Empirical Finance first reported a position in SAGE in Q2 2021 and held it in 4 quarters. The position peaked at $715K in Q2 2021. 209 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

  • Empirical Finance reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Empirical Finance sold 6,745 Sage Therapeutics shares in Q2 2022, an estimated $223K.
  • Empirical Finance first reported a position in Sage Therapeutics in Q2 2021 and held it in 4 quarters.
  • Empirical Finance's Sage Therapeutics position peaked at $715K in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Empirical Finance's 13F filing for Q2 2022, filed 1 Aug 2022.